Role of CYP2C19 pharmacogenetic polymorphism on response of esomeprazole in the treatment of GERD

被引：0
|
作者：
Halimi, Shafarul
Abu Hassan, Muhammad Radzi
Ismail, Rusli
Kiew, Kuang Kiat
Zainuddin, Zalwani
Mustapha, Mohd Nazri
Mokhtar, Suraya
机构：
[1] Univ Sains Malaysia, George Town, Malaysia
[2] Hosp Univ Sains Malaysia, George Town, Malaysia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2013年 / 28卷
关键词：
pharmacogenetics; polymorphism; GERD;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：67 / 68
页数：2
相关论文
共 50 条
  • [41] Association of CYP2C19 Polymorphism with Treatment Response Among Multiple Myeloma Patients on Bortezomib Based Induction Treatment
    Gupta, P.
    Goel, L.
    Kumar, L.
    Singh, A.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (SUPPL 1) : S11 - S11
  • [42] Esomeprazole induced healing of gastroesophageal reflux disease (GERD) is unrelated to Cyp2C19 status - Evidence from clinical and pharmacokinetic data
    Treiber, G
    Leodolter, A
    Klotz, U
    Hofmann, U
    Schwab, M
    Schaeffeler, E
    Malfertheiner, P
    GASTROENTEROLOGY, 2005, 128 (04) : A529 - A529
  • [43] DISTRIBUTION OF THE CYP2C19*2, CYP2C19*3 AND CYP2C19*4 GENE VARIANTS IN A ROMANIAN POPULATION
    Buzoianu, A. D.
    Trifa, A. P.
    Popp, R. A.
    Militaru, C. F.
    Bocsan, C., I
    Popp, I., V
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 80 - 80
  • [44] In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease
    Ohnishi, A
    Murakami, S
    Akizuki, S
    Mochizuki, J
    Echizen, H
    Takagi, I
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (11): : 1221 - 1229
  • [45] CYP2C19 GENETIC POLYMORPHISM ON CLOPIDOGREL RESPONSE IN VIETNAMESE PATIENTS WITH CORONARY STENTING
    Kim, N. T.
    Nguyen, M. N. T.
    Do, D. L.
    Nguyen, Q. H.
    Nguyen, T. T. T.
    Truong, T. H.
    ATHEROSCLEROSIS, 2020, 315 : E83 - E84
  • [46] Evaluation of clopidogrel response variability and identification of the CYP2C19 polymorphism in Mexican patients
    Eva Viveros, Martha
    Arean, Carlos
    Gutierrez, Sergio
    Vazquez, Soledad
    Humberto Cardiel, Mario
    Taboada, Alejandra
    Marin, Gissela
    Solorio, Ruben
    Garcia, Nalley
    ARCHIVOS DE CARDIOLOGIA DE MEXICO, 2016, 86 (04): : 297 - 304
  • [47] The Association Between CYP2C19 Gene Polymorphism and Response to Treatment With Pantoprazole in Patients With Gastroesophageal Reflux Disease
    Altinbas, Akif
    Ekiz, Fuat
    Goktas, Mustafa
    Karaca, Ozgur
    Yilmaz, Baris
    Yasar, Umit
    Coban, Sahin
    Babaoglu, Melih
    Bozkurt, Atilla
    Yuksel, Osman
    GASTROENTEROLOGY, 2013, 144 (05) : S859 - S859
  • [48] Clopidogrel and CYP2C19: Pharmacogenetic Testing Ready for Clinical Prime Time?
    Knauer, Michael J.
    Diamandis, Eleftherios P.
    Hulot, Jean-Sebastien
    Kim, Richard B.
    So, Derek Y. F.
    CLINICAL CHEMISTRY, 2015, 61 (10) : 1235 - 1240
  • [49] The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases
    Alonso-Navarro, Hortensia
    Jimenez-Jimenez, Felix J.
    Garcia-Agundez, Jose A.
    MEDICINA CLINICA, 2006, 126 (18): : 697 - 706
  • [50] CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring
    Aleil, B.
    Leon, C.
    Cazenave, J. -P.
    Gachet, C.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (10) : 1747 - 1749
12345